Outset Medical, Inc. (NASDAQ:OM) Director James F. Hinrichs Acquires 7,500 Shares

Outset Medical, Inc. (NASDAQ:OMGet Rating) Director James F. Hinrichs bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were purchased at an average cost of $17.84 per share, with a total value of $133,800.00. Following the acquisition, the director now directly owns 47,668 shares of the company’s stock, valued at $850,397.12. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Outset Medical Stock Up 11.1 %

Shares of NASDAQ:OM opened at $19.94 on Friday. Outset Medical, Inc. has a 12-month low of $11.41 and a 12-month high of $51.69. The business has a 50 day moving average of $15.88 and a two-hundred day moving average of $17.87. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.24 and a quick ratio of 5.13.

Institutional Trading of Outset Medical

A number of institutional investors and hedge funds have recently made changes to their positions in OM. Assetmark Inc. increased its position in shares of Outset Medical by 387.1% in the second quarter. Assetmark Inc. now owns 1,812 shares of the company’s stock valued at $27,000 after buying an additional 1,440 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Outset Medical during the second quarter worth approximately $27,000. Nisa Investment Advisors LLC increased its position in shares of Outset Medical by 139.5% during the second quarter. Nisa Investment Advisors LLC now owns 2,060 shares of the company’s stock worth $31,000 after purchasing an additional 1,200 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Outset Medical by 38.4% during the third quarter. Tower Research Capital LLC TRC now owns 3,016 shares of the company’s stock worth $48,000 after purchasing an additional 837 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Outset Medical by 56.6% during the third quarter. US Bancorp DE now owns 4,068 shares of the company’s stock worth $65,000 after purchasing an additional 1,471 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Morgan Stanley decreased their target price on Outset Medical from $19.00 to $17.00 and set an “equal weight” rating for the company in a report on Thursday, November 10th. Royal Bank of Canada assumed coverage on Outset Medical in a report on Friday, November 11th. They set an “outperform” rating and a $23.00 target price for the company. Cowen decreased their price target on Outset Medical to $22.00 in a report on Tuesday, November 15th. Cowen decreased their price target on Outset Medical from $33.00 to $22.00 in a report on Wednesday, November 9th. Finally, The Goldman Sachs Group decreased their price target on Outset Medical from $34.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Outset Medical presently has an average rating of “Moderate Buy” and an average target price of $22.83.

About Outset Medical

(Get Rating)

Outset Medical, Inc, a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings.

See Also

Insider Buying and Selling by Quarter for Outset Medical (NASDAQ:OM)

Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.